Clinicians and researchers meet to learn about new research and the latest clinical advances at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
WCO-IOF-ESCEO 2024 London

Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London, UK for the opening of the largest scientific event in the field, the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2024). 

The joint Congress of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) will showcase new clinical research from 1507 submitted abstracts, with a broad scientific programme comprising 10 plenary lectures, 14 Meet-The-Expert sessions, and 7 special and joint symposia, and 41 non-sponsored symposia. Accredited with 22 European CME credits (ECMEC®s), the Congress offers the more than 9000 registrants valuable new knowledge to help them treat patients more effectively in their daily clinical practice. 

Professor Jean-Yves Reginster, ESCEO President and Co-Chair of the Congress, stated, “We’re looking forward to welcoming delegates across the musculoskeletal field from close to 100 countries. Delegates will anticipate three days of stimulating discussion and exciting new science presented by the world’s leading investigators. I’d particularly like to thank the Scientific Programme Committee, headed by Professors René Rizzoli, John Kanis, Cyrus Cooper, and Nicholas Harvey, for planning this outstanding scientific programme.” 

The plenary session topics to be covered during the Congress include: primary and secondary fracture prevention, osteoporosis management, vitamin D, bone and chronic kidney disease, bone resorption inhibitors, management of osteoporosis in multi-ethnic societies, sarcopenia, osteoarthritis management, and assessment of fracture risk. Meet-the-Expert sessions and Non-Sponsored symposia will address further topics of clinical importance including secondary fracture prevention, nutrition, fracture healing, cancer and bone, and vertebral fracture detection, among other topics.

The seven special and joint symposia planned reflect the important and ongoing collaborations across the musculoskeletal field. These include the WHO Symposium on Bone Health and Ageing; DVO-ESCEO Joint Symposium; EUGMS-ESCEO Joint Symposium- Improving Fragility Fracture Care: a multidisciplinary perspective; OARSI-ESCEO Joint Symposium - Managing Bone and Joint Diseases in Older Aged: Epidemiology and Lessons for the Clinic; ESCEO Working Group Symposium on REMS in the diagnosis and management of osteoporosis; and SICOT-ESCEO-IOF Symposium - Surgical Treatment of Fragility Fractures.

IOF Honorary President and Congress Co-Chair Professor John Kanis added, “Musculoskeletal disorders pose a significant societal and health-economic burden, and are primary drivers of disability, diminished quality of life and early death around the world. Our Congress programme will equip clinicians with knowledge of the latest clinical breakthroughs and new research, empowering them to deliver optimal care to their patients.”

The WCO-IOF-ESCEO 2024 continues at the Hilton Metropole in London until April 14th.  

About the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO)
Held jointly by IOF and ESCEO, the WCO-IOF-ESCEO annual congress is the world’s largest forum for the presentation of clinical research and new advances in the prevention and management of musculoskeletal disorders, including osteoporosis, osteoarthritis, sarcopenia, and frailty. The WCO-IOF-ESCEO 2024 is being held from April 11-14, 2024 in London, UK.
For complete information visit 

The next WCO-IOF-ESCO is planned from April 10-13, 2025 in Rome, Italy.  

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policymakers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

About IOF
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as more than 330 patient, medical and research organizations, work together to make fracture prevention and healthy mobility a worldwide healthcare priority.  @iofbonehealth